Charles River’s experience with oncology drug development spans all phases, from target identification to IND. Utilizing the most effective combination of tools available to identify promising compounds, our broad range of models and support services allows clients to choose the most appropriate study design and screening method to identify promising compounds and optimize lead candidates.

Syngeneic Models in Cancer Immunotherapy

In this webinar, learn how we can help you choose the best models to predict sensitivity to targeted therapies.

Watch Replay »

I need to...